

SEQUENCE LISTING

<110> Bayer HealthCare AG

<120> Diagnostics and Therapeutics for Diseases Associated with
Kallikrein 12 (KLK12)

<130> BHC 04 01 018

<160> 5

<170> PatentIn version 3.2

<210> 1

<211> 1074

<212> DNA

<213> Homo sapiens

<400> 1

```

gcaggtaggt ggacggagag atagcagcga cgaggacagg ccaaacagtg acagccacgt      60
agaggatctg gcagacaaag agacaagggtg agaaggagac tttggaagtg acccaccatg      120
gggctcagca tctttttgct cctgtgtgtt cttgggctca gccaggcagc cacaccgaag      180
attttcaatg gcactgagtg tgggcgtaac tcacagccgt ggcaggtggg gctgtttgag      240
ggcaccagcc tgcgctgcgg ggggtgtcctt attgaccaca ggtgggtcct cacagcggct      300
cactgcagcg gcagcaggta ctgggtgcgc ctgggggaac acagcctcag ccagctcgac      360
tggaccgagc agatccggca cagcggcttc tctgtgacct atcccggtta cctgggagcc      420
tcgacgagcc acgagcacga cctccggctg ctgcggctgc gcctgcccgt ccgcgtaacc      480
agcagcgttc aaccctgcc cctgcccaat gactgtgcaa ccgctggcac cgagtgccac      540
gtctcaggct ggggcatcac caaccaccca cggaacccat tcccggatct gctccagtgc      600
ctcaacctct ccatcgtctc ccattgccac tgccatggtg tgtatcccgg gagaatcacg      660
agcaacatgg tgtgtgcagg cggcgtcccg gggcaggatg cctgccaggg tgattctggg      720
ggccccctgg tgtgtggggg agtccttcaa ggtctggtgt cctgggggtc tgtggggccc      780
tgtggacaag atggcatccc tggagtctac acctatattt gcaagtatgt ggactggatc      840
cggatgatca tgaggaacaa ctgacctgtt tcctccacct ccaccccac cccttaactt      900
gggtacccct ctggccctca gagcaccaat atctcctcca tcaactcccc tagctccact      960
cttgttggcc tgggaacttc ttggaacttt aactcctgcc agcccttcta agaccacga     1020
gcggggtgag agaagtgtgc aatagtctgg aataaatata aatgaaggag gggc         1074

```

<210> 2

<211> 248

<212> PRT

<213> Homo sapiens

<400> 2

- 2 -

Met Gly Leu Ser Ile Phe Leu Leu Leu Cys Val Leu Gly Leu Ser Gln
 1 5 10 15
 Ala Ala Thr Pro Lys Ile Phe Asn Gly Thr Glu Cys Gly Arg Asn Ser
 20 25 30
 Gln Pro Trp Gln Val Gly Leu Phe Glu Gly Thr Ser Leu Arg Cys Gly
 35 40 45
 Gly Val Leu Ile Asp His Arg Trp Val Leu Thr Ala Ala His Cys Ser
 50 55 60
 Gly Ser Arg Tyr Trp Val Arg Leu Gly Glu His Ser Leu Ser Gln Leu
 65 70 75 80
 Asp Trp Thr Glu Gln Ile Arg His Ser Gly Phe Ser Val Thr His Pro
 85 90 95
 Gly Tyr Leu Gly Ala Ser Thr Ser His Glu His Asp Leu Arg Leu Leu
 100 105 110
 Arg Leu Arg Leu Pro Val Arg Val Thr Ser Ser Val Gln Pro Leu Pro
 115 120 125
 Leu Pro Asn Asp Cys Ala Thr Ala Gly Thr Glu Cys His Val Ser Gly
 130 135 140
 Trp Gly Ile Thr Asn His Pro Arg Asn Pro Phe Pro Asp Leu Leu Gln
 145 150 155 160
 Cys Leu Asn Leu Ser Ile Val Ser His Ala Thr Cys His Gly Val Tyr
 165 170 175
 Pro Gly Arg Ile Thr Ser Asn Met Val Cys Ala Gly Gly Val Pro Gly
 180 185 190
 Gln Asp Ala Cys Gln Gly Asp Ser Gly Gly Pro Leu Val Cys Gly Gly
 195 200 205
 Val Leu Gln Gly Leu Val Ser Trp Gly Ser Val Gly Pro Cys Gly Gln
 210 215 220
 Asp Gly Ile Pro Gly Val Tyr Thr Tyr Ile Cys Lys Tyr Val Asp Trp
 225 230 235 240
 Ile Arg Met Ile Met Arg Asn Asn
 245

<210> 3

<211> 20

<212> DNA

<213> artificial sequence

<220>

<223> forward primer

<400> 3

ctcttgttg cctgggaact

20

<210> 4

<211> 19
<212> DNA
<213> artificial sequence

<220>
<223> reverse primer

<400> 4
cgcctcgtgg gtcttagaa 19

<210> 5
<211> 25
<212> DNA
<213> artificial sequence

<220>
<223> probe

<400> 5
cttggaactt taactcctgc cagcc 25